A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.
Wave crashes on obesity disappointment
There’s a reason lots of companies are working on GLP-1-based drugs for obesity: The other stuff tends not to work. The latest biotech to learn



